Trial Profile
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms OVAL
- Sponsors VBL Therapeutics
- 31 Oct 2023 Results evaluating whether the addition of ofranergene obadenovec to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer , published in the Journal of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2023 Status changed to completed.